Drug Type Small molecule drug |
Synonyms 依奉阿克 + [1] |
Target |
Mechanism ALK inhibitors(Anaplastic lymphoma kinase inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors), c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (11 Jun 2024), |
RegulationSpecial Review Project (CN) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
ALK positive Non-Small Cell Lung Cancer | CN | 11 Jun 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 2 | CN | 04 Aug 2020 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 01 Feb 2021 | |
MET gene amplification Non-small Cell Lung Cancer | Phase 1 | CN | 11 Aug 2020 | |
Advanced cancer | Phase 1 | CN | 12 Jul 2017 |
Phase 3 | ALK positive Non-Small Cell Lung Cancer First line | 264 | ieqtybgruh(knbnzupigy) = yaqzjcdwng nbqmfgsxlc (uezzrsuqni ) View more | Positive | 14 Aug 2023 | ||
ieqtybgruh(knbnzupigy) = oquciijgpu nbqmfgsxlc (uezzrsuqni ) View more | |||||||
Phase 1 | 63 | (sewxugflgx) = 76.1% binipbaunh (xssarhsvci ) View more | Positive | 05 Aug 2022 |